choline kinase betaGenealiases: CHETK · CHKL · CK · CKB · CKEKB · EK
Q-omics provides the consensus-scored CHKB profile across patient tissues and cancer cell-line models. CHKB expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHKB is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CHKB protein abundance shows 25,903 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where CHKB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHKB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHKB survival associations across molecular data types. CHKB RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHKB RNA expression–survival associations across cancer types. High CHKB expression shows unfavorable associations in KIRC, ACC, UVM, LIHC and STAD, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHKB RNA expression.
This table summarizes CHKB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CHKB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHKB shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, STAD, COAD and CHOL. The KIRC box plot shows higher CHKB RNA expression in tumor versus normal tissue (log2 FC = +0.360, t-test p < 0.001).
This table shows molecular features associated with CHKB in patient tissues and cancer cell lines. In patient samples, CHKB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHKB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
